Clinical Trial News and Research

RSS

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.

15 Sep 2010

RAB-1 monoclonal antibody study shows positive result for rabies

With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

15 Sep 2010

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARC-4558 for the treatment of pain associated with Painful Diabetic Neuropathy (PDN).

15 Sep 2010

ACT receives patent for RPE cells to treat retinal degeneration

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it will be issued U.S. Patent Numbers 7,795,025 and 7,794,704 on Tuesday, September 14th, which continue to extend the company's patent portfolio covering its retinal pigment epithelial (RPE) cell programs.

15 Sep 2010

Hormone melatonin improves egg quality in IVF

Poor egg (oocyte) quality is an important cause of female infertility. Low quality eggs may have several problems, for example they may not divide properly, or they may be missing certain chromosomes. Egg quality also declines with age, and certain medical conditions, such as PolyCystic Ovary Syndrome, can lead to poor quality eggs.

15 Sep 2010

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

15 Sep 2010

Stemedica Cell Technologies completes master bank of mesenchymal bone marrow-derived stem cells

Stemedica Cell Technologies, Inc., a world leader in adult stem cell manufacturing and research, announced today that it has completed its proprietary master bank of mesenchymal bone marrow-derived stem cells.

14 Sep 2010

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.

14 Sep 2010

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.

14 Sep 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

AACR, EmergingMed collaborate to connect cancer patients with clinical trials in connection to SU2C broadcast

The American Association for Cancer Research (AACR) announces its collaboration with the clinical trial navigation system EmergingMed, to connect patients with clinical trials in connection to the Stand Up To Cancer (SU2C) broadcast which took place on Sept. 10, at 8 p.m. EDT & PDT / 7 p.m. CDT. The AACR-SU2C Clinical Trials Finder provides a resource for cancer patients and their loved ones to identify clinical trials that may be appropriate for their particular diagnosis, stage and treatment history.

14 Sep 2010

$Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL$

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

Cell Therapeutics, Inc. today announced that it intends to appeal the U.S. Food and Drug Administration's previously disclosed decision regarding the pixantrone New Drug Application ("NDA") to treat patients with relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL").

14 Sep 2010

AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program). The grant will fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Leber congenital amaurosis (LCA), a genetic retinal disease known to cause blindness at an early age.

14 Sep 2010

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for Fluzone® Intradermal (Influenza Virus Vaccine). The file has been accepted by the FDA and an action date is anticipated in the first half of 2011.

From BD (Becton, Dickinson and Company) 14 Sep 2010

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

St. John Hospital and Medical Center in Detroit and Avinger, Inc., a medical device company focused on the development of innovative devices to combat peripheral artery disease, announced today the enrollment of the first patient in the CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial.

14 Sep 2010

Arno Therapeutics closes private placement to advance cancer treatment

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $15 million.

14 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Capstone Therapeutics reaches overall progress in AZX100 Phase 2a clinical trials for keloid scarring

Capstone Therapeutics announced today that participating subjects have reached the planned twelve-month timepoint in the first of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. Data analysis for these subjects is underway. Per protocol and the original clinical development plan, results of the two keloid scarring trials will be pooled for analytical purposes and are scheduled for release during 4Q2010.

14 Sep 2010

Laser acupuncture a plausible treatment for depression

Acupuncture produces significant changes in parts of the brain that regulate emotional states and is a biologically plausible treatment for depression and other neuropsychiatric disorders, Australian researchers have shown for the first time.

13 Sep 2010

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

An antibiotic appears to be a safe treatment for stroke and a good companion therapy for tPA, the clot buster that is currently the only FDA-approved drug therapy, researchers report.

13 Sep 2010

Clinical Trial News and Research

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

RAB-1 monoclonal antibody study shows positive result for rabies

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

ACT receives patent for RPE cells to treat retinal degeneration

Hormone melatonin improves egg quality in IVF

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Stemedica Cell Technologies completes master bank of mesenchymal bone marrow-derived stem cells

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

AACR, EmergingMed collaborate to connect cancer patients with clinical trials in connection to SU2C broadcast

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

Arno Therapeutics closes private placement to advance cancer treatment

Study finds new therapeutic target for polycystic kidney disease

Capstone Therapeutics reaches overall progress in AZX100 Phase 2a clinical trials for keloid scarring

Laser acupuncture a plausible treatment for depression

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer